OUTPERFORM: We initiate coverage on AlzeCure Pharma with a step wise valuation approach. For 2019, we see a reasonable valuation range between SEK17-20 per share suggesting 102-138% upside to the current share price. For 2020, we see a range between SEK29-34 per share suggesting 245-305% upside to the current share price.
First-in-class tablets, team with significant big pharma experience
AlzeCure Pharma is a Swedish-based pharmaceutical company with potentially first-in-class proprietary and novel targeted small molecule (tablets) candidates for neurodegenerative diseases with a primary target on Alzheimer’s Disease (AD). AlzeCure’s management team has extensive big pharma experience, and formed an integral part of AstraZeneca’s CNS department.
Marketing material commissioned by AlzeCure Pharma